ER Inhibitors
1 drugsAbout ER
The Estrogen Receptor (ER) is a ligand-activated transcription factor within the nuclear receptor superfamily, crucial for regulating gene expression in response to estrogen hormones. It plays a key role in various physiological processes, making it a significant drug target.
ER is a therapeutic target despite the lack of genetic evidence directly linking it to specific diseases. Its involvement in multiple physiological processes has driven therapeutic interventions.
ER is targeted by 5 FDA-approved drugs, including CERIANNA, INLURIYO, ORSERDU, and DUAVEE (approved for two indications). All approved drugs are small molecules, with applications in oncology (3 drugs) and other therapeutic areas (2 drugs).
Top ER Drugs
Four companies have approved drugs targeting ER, including GE HEALTHCARE, Eli Lilly, STEMLINE THERAP, and Pfizer.
The presence of multiple players suggests a moderately competitive market with potential for differentiation.
ER Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets ER, using small molecule modality.
Exploring alternative modalities like antibodies or PROTACs could provide a competitive advantage.
ER Clinical Trials 1 trial
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on ER. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
ER Drug Approval Timeline (2020 - 2020)
The first ER-targeting drug was approved in 2013, with the most recent approval in 2025.
The recent approval suggests continued interest and potential for further drug development targeting ER.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 1 (0 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on ER. A trial counts if an approved drug acting on ER is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.